应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
ADTX ADiTx Therapeutics
盘后交易 01-13 18:16:56 EST
0.7479
-0.0669
-8.21%
盘后
0.7384
-0.0095
-1.27%
17:57 EST
最高
0.8150
最低
0.7309
成交量
26.63万
今开
0.8149
昨收
0.8148
日振幅
10.32%
总市值
132.83万
流通市值
132.83万
总股本
177.60万
成交额
20.19万
换手率
15.00%
流通股本
177.60万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Aditxt发布Bitxbio™增长愿景的最新进展、计划中的数字资产国库、Pearsanta的IPO计划和Evofem的国家上市恢复计划
美股速递 · 2025-11-18
Aditxt发布Bitxbio™增长愿景的最新进展、计划中的数字资产国库、Pearsanta的IPO计划和Evofem的国家上市恢复计划
Aditxt, Inc.(纳斯达克:ADTX)宣布于2025年11月3日交易开始时实施1股换113股的反向股拆分
美股速递 · 2025-10-30
Aditxt, Inc.(纳斯达克:ADTX)宣布于2025年11月3日交易开始时实施1股换113股的反向股拆分
Aditxt子公司Pearsanta启动首个人体研究的招募,研究针对影响全球1.9亿女性的子宫内膜异位症的血液检测,全球市场规模达14.5亿美元
美股速递 · 2025-10-27
Aditxt子公司Pearsanta启动首个人体研究的招募,研究针对影响全球1.9亿女性的子宫内膜异位症的血液检测,全球市场规模达14.5亿美元
Evofem Biosciences Inc: 向Aditxt发送终止通知,宣布行使终止合并协议的权利
美股速递 · 2025-10-21
Evofem Biosciences Inc: 向Aditxt发送终止通知,宣布行使终止合并协议的权利
加载更多
公司概况
公司名称:
ADiTx Therapeutics
所属市场:
NASDAQ
上市日期:
--
主营业务:
Aditxt, Inc.于2017年9月28日根据特拉华州法律注册成立。该公司是一家临床前阶段的生命科学公司,致力于延长移植患者的生命和提高移植患者的生活质量。他们拥有独家全球许可证,用于将这种基于核酸的技术称为Apoptotic DNA Immunotherapy(ADi),该技术利用新的方法模仿他们的身体自然诱导对自身组织的耐受性。该公司计划开发用于器官移植,植皮和创伤愈合的ADi产品,最初的重点是皮肤移植和其他器官和组织同种异体移植。
发行价格:
--
{"stockData":{"symbol":"ADTX","market":"US","secType":"STK","nameCN":"ADiTx Therapeutics","latestPrice":0.7479,"timestamp":1768338000000,"preClose":0.8148,"halted":0,"volume":266319,"hourTrading":{"tag":"盘后","latestPrice":0.7384,"preClose":0.7479,"latestTime":"17:57 EST","volume":1797,"amount":1345.30597218,"timestamp":1768345061521},"delay":0,"floatShares":1776000,"shares":1776000,"eps":-4919.3423,"marketStatus":"盘后交易","change":-0.0669,"latestTime":"01-13 18:16:56 EST","open":0.8149,"high":0.815,"low":0.7309,"amount":201897.77614776,"amplitude":0.103216,"askPrice":0.811,"askSize":500,"bidPrice":0.72,"bidSize":1001,"shortable":0,"etf":0,"ttmEps":-4919.3423,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1768352400000},"marketStatusCode":4,"adr":0,"listingDate":1593489600000,"exchange":"NASDAQ","adjPreClose":0.8148,"preHourTrading":{"tag":"盘前","latestPrice":0.8149,"preClose":0.8148,"latestTime":"09:29 EST","volume":11232,"amount":8914.42573632,"timestamp":1768314587547},"postHourTrading":{"tag":"盘后","latestPrice":0.7384,"preClose":0.7479,"latestTime":"17:57 EST","volume":1797,"amount":1345.30597218,"timestamp":1768345061521},"volumeRatio":1.135931,"impliedVol":6.3423,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/ADTX","defaultTab":"news","newsList":[{"id":"1122736896","title":"Aditxt发布Bitxbio™增长愿景的最新进展、计划中的数字资产国库、Pearsanta的IPO计划和Evofem的国家上市恢复计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1122736896","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122736896?lang=zh_cn&edition=full","pubTime":"2025-11-18 21:01","pubTimestamp":1763470887,"startTime":"0","endTime":"0","summary":"Aditxt发布了关于其Bitxbio™增长愿景的最新进展,包括计划中的数字资产国库、Pearsanta的IPO计划以及Evofem恢复国家上市的计划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADTX"],"gpt_icon":0},{"id":"1162019859","title":"Aditxt, Inc.(纳斯达克:ADTX)宣布于2025年11月3日交易开始时实施1股换113股的反向股拆分","url":"https://stock-news.laohu8.com/highlight/detail?id=1162019859","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162019859?lang=zh_cn&edition=full","pubTime":"2025-10-30 04:32","pubTimestamp":1761769974,"startTime":"0","endTime":"0","summary":"Aditxt, Inc.(纳斯达克:ADTX)宣布于2025年11月3日交易开始时实施1股换113股的反向股拆分。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADTX","BK4139"],"gpt_icon":0},{"id":"1194082919","title":"Aditxt子公司Pearsanta启动首个人体研究的招募,研究针对影响全球1.9亿女性的子宫内膜异位症的血液检测,全球市场规模达14.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1194082919","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194082919?lang=zh_cn&edition=full","pubTime":"2025-10-27 20:30","pubTimestamp":1761568218,"startTime":"0","endTime":"0","summary":"Aditxt子公司Pearsanta启动首个人体研究的招募,研究针对影响全球1.9亿女性的子宫内膜异位症的血液检测,全球市场规模达14.5亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADTX","BK4139"],"gpt_icon":0},{"id":"1133028071","title":"Evofem Biosciences Inc: 向Aditxt发送终止通知,宣布行使终止合并协议的权利","url":"https://stock-news.laohu8.com/highlight/detail?id=1133028071","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133028071?lang=zh_cn&edition=full","pubTime":"2025-10-21 06:00","pubTimestamp":1760997611,"startTime":"0","endTime":"0","summary":"Evofem Biosciences Inc: 向Aditxt发送终止通知,宣布行使终止合并协议的权利","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","BK4007","ADTX","EVFM","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aditxt.com","stockEarnings":[{"period":"1week","weight":-0.1438},{"period":"1month","weight":-0.6363},{"period":"3month","weight":-0.9848},{"period":"6month","weight":-0.9939},{"period":"1year","weight":-0.9998},{"period":"ytd","weight":-0.0236}],"compareEarnings":[{"period":"1week","weight":0.0108},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0497},{"period":"6month","weight":0.1136},{"period":"1year","weight":0.1975},{"period":"ytd","weight":0.0194}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Aditxt, Inc.于2017年9月28日根据特拉华州法律注册成立。该公司是一家临床前阶段的生命科学公司,致力于延长移植患者的生命和提高移植患者的生活质量。他们拥有独家全球许可证,用于将这种基于核酸的技术称为Apoptotic DNA Immunotherapy(ADi),该技术利用新的方法模仿他们的身体自然诱导对自身组织的耐受性。该公司计划开发用于器官移植,植皮和创伤愈合的ADi产品,最初的重点是皮肤移植和其他器官和组织同种异体移植。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.014211},{"month":2,"riseRate":0,"avgChangeRate":-0.207727},{"month":3,"riseRate":0.2,"avgChangeRate":-0.169474},{"month":4,"riseRate":0.2,"avgChangeRate":-0.266324},{"month":5,"riseRate":0.2,"avgChangeRate":-0.125836},{"month":6,"riseRate":0,"avgChangeRate":-0.251138},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.120854},{"month":8,"riseRate":0.166667,"avgChangeRate":0.274702},{"month":9,"riseRate":0,"avgChangeRate":-0.488285},{"month":10,"riseRate":0,"avgChangeRate":-0.418091},{"month":11,"riseRate":0.166667,"avgChangeRate":-0.288889},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.245759}],"exchange":"NASDAQ","name":"ADiTx Therapeutics","nameEN":"ADiTx Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ADiTx Therapeutics(ADTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ADiTx Therapeutics(ADTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ADiTx Therapeutics,ADTX,ADiTx Therapeutics股票,ADiTx Therapeutics股票老虎,ADiTx Therapeutics股票老虎国际,ADiTx Therapeutics行情,ADiTx Therapeutics股票行情,ADiTx Therapeutics股价,ADiTx Therapeutics股市,ADiTx Therapeutics股票价格,ADiTx Therapeutics股票交易,ADiTx Therapeutics股票购买,ADiTx Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ADiTx Therapeutics(ADTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ADiTx Therapeutics(ADTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}